Drug Patents owned by Mallinckrodt Hosp

1. Drug name - INOMAX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8846112 MALLINCKRODT HOSP Methods of distributing a pharmaceutical product comprising nitric oxide gas for inhalation Jun, 2029

(6 years from now)

US8795741 MALLINCKRODT HOSP Methods for treating patients who are candidates for inhaled nitric oxide treatment Jun, 2029

(6 years from now)

US8293284 MALLINCKRODT HOSP Methods of reducing the risk of occurrence of pulmonary edema in term or near-term neonates in need of treatment with inhaled nitric oxide Jun, 2029

(6 years from now)

US8431163 MALLINCKRODT HOSP Methods of reducing the risk of occurrence of pulmonary edema associated with inhalation of nitric oxide gas Jun, 2029

(6 years from now)

US8282966 MALLINCKRODT HOSP Methods of reducing the risk of occurrence of pulmonary edema in children in need of treatment with inhaled nitric oxide Jun, 2029

(6 years from now)

US8846112

(Pediatric)

MALLINCKRODT HOSP Methods of distributing a pharmaceutical product comprising nitric oxide gas for inhalation Dec, 2029

(7 years from now)

US8282966

(Pediatric)

MALLINCKRODT HOSP Methods of reducing the risk of occurrence of pulmonary edema in children in need of treatment with inhaled nitric oxide Dec, 2029

(7 years from now)

US8293284

(Pediatric)

MALLINCKRODT HOSP Methods of reducing the risk of occurrence of pulmonary edema in term or near-term neonates in need of treatment with inhaled nitric oxide Dec, 2029

(7 years from now)

US8431163

(Pediatric)

MALLINCKRODT HOSP Methods of reducing the risk of occurrence of pulmonary edema associated with inhalation of nitric oxide gas Dec, 2029

(7 years from now)

US8795741

(Pediatric)

MALLINCKRODT HOSP Methods for treating patients who are candidates for inhaled nitric oxide treatment Dec, 2029

(7 years from now)

US8573209 MALLINCKRODT HOSP Gas delivery device and system Jan, 2031

(8 years from now)

US8776795 MALLINCKRODT HOSP Gas delivery device and system Jan, 2031

(8 years from now)

US9265911 MALLINCKRODT HOSP Gas delivery device and system Jan, 2031

(8 years from now)

US9408993 MALLINCKRODT HOSP Nitric oxide delivery device Jan, 2031

(8 years from now)

US8776794 MALLINCKRODT HOSP Nitric oxide delivery device Jan, 2031

(8 years from now)

US8573210 MALLINCKRODT HOSP Nitric oxide delivery device Jan, 2031

(8 years from now)

US8291904 MALLINCKRODT HOSP Gas delivery device and system Jan, 2031

(8 years from now)

US9295802 MALLINCKRODT HOSP Gas delivery device and system Jan, 2031

(8 years from now)

US8776795

(Pediatric)

MALLINCKRODT HOSP Gas delivery device and system Jul, 2031

(8 years from now)

US8291904

(Pediatric)

MALLINCKRODT HOSP Gas delivery device and system Jul, 2031

(8 years from now)

US8776794

(Pediatric)

MALLINCKRODT HOSP Nitric oxide delivery device Jul, 2031

(8 years from now)

US8573209

(Pediatric)

MALLINCKRODT HOSP Gas delivery device and system Jul, 2031

(8 years from now)

US8573210

(Pediatric)

MALLINCKRODT HOSP Nitric oxide delivery device Jul, 2031

(8 years from now)

US9295802

(Pediatric)

MALLINCKRODT HOSP Gas delivery device and system Jul, 2031

(8 years from now)

US9408993

(Pediatric)

MALLINCKRODT HOSP Nitric oxide delivery device Jul, 2031

(8 years from now)

US9265911

(Pediatric)

MALLINCKRODT HOSP Gas delivery device and system Jul, 2031

(8 years from now)

US9279794 MALLINCKRODT HOSP Systems and methods for compensating long term sensitivity drift of electrochemical gas sensors exposed to nitric oxide Feb, 2034

(11 years from now)

US9279794

(Pediatric)

MALLINCKRODT HOSP Systems and methods for compensating long term sensitivity drift of electrochemical gas sensors exposed to nitric oxide Aug, 2034

(11 years from now)

US9770570 MALLINCKRODT HOSP Apparatus and method for monitoring nitric oxide delivery May, 2036

(13 years from now)

US9770570

(Pediatric)

MALLINCKRODT HOSP Apparatus and method for monitoring nitric oxide delivery Nov, 2036

(14 years from now)

Drugs and Companies using NITRIC OXIDE ingredient

Treatment: A method of reducing the risk of pulmonary edema in patients in need of treatment with inhaled nitric oxide; A method of providing a predetermined concentration of nitric oxide to a patient; A method of providing nitric oxide therapy to a patient by verifying gas information of nitric oxide prior to delivery to patient; A method of treating hypoxic respiratory failure by verifying gas information of nitric oxide prior to delivery to patient; A method of providing nitric oxide therapy to a patient by compensating long-term sensitivity drift of electrochemical gas sensors used in systems for delivering therapeutic nitric oxide to a patient; A method of providing nitric oxide therapy to a patient by measuring and displaying an indication of the calculated delivery concentration of nitiric oxide as compared to the desired delivery concentration of nitric oxide

Dosage: GAS;INHALATION

More Information on Dosage
Strength Dosage Availability
100PPM GAS;INHALATION Discontinued
800PPM GAS;INHALATION Prescription

2. Drug name - OFIRMEV

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9610265 MALLINCKRODT HOSP Reduced dose intravenous acetaminophen Nov, 2028

(6 years from now)

US9987238 MALLINCKRODT HOSP Reduced dose intravenous acetaminophen Nov, 2028

(6 years from now)

US10383834 MALLINCKRODT HOSP Reduced dose intravenous acetaminophen Nov, 2028

(6 years from now)

US9610265

(Pediatric)

MALLINCKRODT HOSP Reduced dose intravenous acetaminophen May, 2029

(6 years from now)

US9987238

(Pediatric)

MALLINCKRODT HOSP Reduced dose intravenous acetaminophen May, 2029

(6 years from now)

US9399012 MALLINCKRODT HOSP Reduced dose intravenous acetaminophen Sep, 2031

(8 years from now)

US9399012

(Pediatric)

MALLINCKRODT HOSP Reduced dose intravenous acetaminophen Mar, 2032

(9 years from now)

Drugs and Companies using ACETAMINOPHEN ingredient

Treatment: Modified dosing regimen for the management of moderate to severe pain with adjunctive opioid analgesics; Modified dosing regimen for the management of mild to moderate pain or management of moderate to severe pain as an adjunct to opioid analgesics; Modified dosing regimen for the reduction of fever; modified dosing regimen for the management of mild to moderate pain; Modified dosing regimen for the reduction of fever; modified dosing regimen for the management of mild to moderate pain or management of moderate to severe pain as an adjunct to opioid analgesics

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
1GM/100ML (10MG/ML) SOLUTION;INTRAVENOUS Discontinued

availability in other generic markets.

Click on the highlighted region to filter.